Parkin et al. Ca cancer j clin. 2005;55: 74-108. Parkin et al. Ca cancer j clin. 2005;55: 74-108



Yüklə 450 b.
tarix05.03.2018
ölçüsü450 b.



Parkin et al. CA Cancer J Clin. 2005;55:74-108.

  • Parkin et al. CA Cancer J Clin. 2005;55:74-108.



Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy

  • Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy

    • 80%-85% respond to first-line therapy
    • Newer regimens including molecular targeted therapy are under investigation
    • Most patients develop disease recurrence within 2 years of diagnosis
  • Long-term remission dependent upon surgical/chemotherapy approach

  • Several agents active in the second-line setting, resulting in improved progression-free and overall survival











Patient/disease factors – heterogeneous disease

  • Patient/disease factors – heterogeneous disease

    • Prior complete debulking or initial FIGO I/II
    • Ascites > 500ml
    • Performance status ECOG 0
    • Age
    • Presence/absence of symptoms
    • Platin-based chemotherapy
    • Parenchymal involvement
    • Relapse-free vs treatment-free interval (TFI)


Patient/disease factors – heterogeneous disease

  • Patient/disease factors – heterogeneous disease

    • Prior complete debulking or initial FIGO I/II
    • Ascites > 500ml
    • Performance status ECOG 0
    • Age
    • Presence/absence of symptoms
    • Platin-based chemotherapy
    • Parenchymal involvement
    • Relapse-free vs treatment-free interval (TFI)


E. Pujade-Lauraine et al.

  • E. Pujade-Lauraine et al.



Gadducci et al. Anticancer Res. 2001;21:3525-3533.

  • Gadducci et al. Anticancer Res. 2001;21:3525-3533.



Bookman. The Oncologist. 1999;4:87-94.

  • Bookman. The Oncologist. 1999;4:87-94.



Cure

  • Cure

  • Survival prolongation

  • Achievement of durable objective response

  • Improvement in cancer-related symptoms

  • Maintenance of quality of life (tend to correlate with response rate)

  • Delayed time to (symptomatic) disease progression









Dostları ilə paylaş:


Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2019
rəhbərliyinə müraciət

    Ana səhifə